Search Results

0 results for 'Viela Bio'

You can use to get even better search results
August 21, 2024 | Delaware Business Court Insider

Minority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company's Business Affairs

The actual control theory is "not easy to satisfy." In its recent decision, Scianella v. AstraZeneca UK Limited, C.A. No. 2023-0125-PAF (Del. Ch. July 8, 2024), the Delaware Court of Chancery emphasized that plaintiffs have a steep burden even at the pleadings stage to demonstrate actual control.
5 minute read
August 19, 2024 | Litigation Daily

Litigation Leaders: Adam Siegel of Freshfields on Four 'Cs' of the Firm's Litigation Practice

Siegel, who joined Freshfields Bruckhaus Deringer more than 15 years ago to help start its white-collar practice in the U.S., says the words "commercial," "creativity," "collegiality" and "cross-border" are "core" to the firm's litigation department.
9 minute read
July 09, 2024 | Litigation Daily

Runners-Up and Shout-Outs From Before the 4th

Here's a look at some of the wins that landed in the run-up to the Independence Day holiday.
7 minute read
November 02, 2023 | The Recorder

'We Have a Whole Ecosystem': Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to Come

"It was a career deal for me. Horizon was such an important client to me personally … it's bittersweet. I'll miss them, but I'm happy for the great outcome," said Borden, a finalist for the California Legal Awards' Attorney of the Year.
6 minute read
September 08, 2023 | Litigation Daily

Litigators of the Week: Cravath and Cooley Clear a Path for Amgen's $27.8B Acquisition of Horizon Therapeutics

The FTC and six state attorneys general dropped their challenge to the merger just 10 days after litigators at Cravath, Swaine & Moore and Cooley, repping Amgen and Horizon respectively, filed opposition briefs pushing back against the agency's preliminary injunction bid.
11 minute read
February 06, 2023 | Delaware Business Court Insider

Class Alleges AstraZeneca's $3B Spin-Off Sold for Inadequate Price

This suit was surfaced by Law.com Radar. Read the complaint here.
1 minute read

Resources

  • 2024 Trends Report Mid-Year Special Edition: Update on Outside Counsel Billing Rates

    Brought to you by LexisNexis® CounselLink®

    Download Now

  • AI in Private Equity: A Guide for Gaining an Early Advantage

    Brought to you by Ontra

    Download Now

  • Why Are So Many Law Firms Suddenly Embracing Digital Transformation?

    Brought to you by AllRize

    Download Now

  • 2025 State Legislative Sessions

    Brought to you by LexisNexis®

    Download Now